BLOOD COAGULATION & FIBRINOLYSIS
Scope & Guideline
Connecting Researchers to the Future of Blood Science
Introduction
Aims and Scopes
- Coagulation Disorders and Thrombosis:
The journal covers various aspects of coagulation disorders, including inherited and acquired thrombophilias, immune thrombocytopenic purpura, and other thrombotic conditions, focusing on their pathophysiology, diagnosis, and management. - Clinical Outcomes and Treatment Strategies:
Research published in the journal often explores clinical outcomes associated with different treatment modalities, including novel therapies for hemophilia, anticoagulation strategies, and the effectiveness of new drugs. - Laboratory Diagnostics and Methodologies:
A significant part of the journal is dedicated to advancements in laboratory diagnostics, including the evaluation of coagulation assays, thromboelastometry, and the development of new diagnostic techniques for bleeding disorders. - Genetic and Molecular Studies:
The journal also emphasizes genetic studies related to coagulation factors and their mutations, providing insights into the molecular basis of bleeding disorders and potential therapeutic targets. - Epidemiological Studies:
Epidemiological research focusing on the prevalence, risk factors, and socio-economic impact of coagulation disorders is a key area of interest, contributing to the understanding of these conditions at a population level.
Trending and Emerging
- Impact of COVID-19 on Coagulation:
Research investigating the effects of COVID-19 on coagulation and thrombotic risk has surged, reflecting the pandemic's significant impact on health and its implications for patients with pre-existing coagulation disorders. - Innovative Therapies and Treatments:
There is an increasing number of studies focusing on innovative therapies for treating thrombotic and bleeding disorders, including targeted therapies and novel agents like caplacizumab and emicizumab. - Real-World Evidence and Outcomes Research:
The journal is increasingly publishing studies that provide real-world evidence regarding treatment outcomes, emphasizing the importance of clinical effectiveness data in everyday practice. - Integration of Genetic Testing in Management:
Emerging themes include the integration of genetic testing into the management of coagulation disorders, highlighting the growing importance of personalized medicine in this field. - Interdisciplinary Approaches to Hemostasis:
There is a trend towards interdisciplinary research that incorporates insights from immunology, oncology, and infectious diseases, reflecting the complex interactions between coagulation and other bodily systems.
Declining or Waning
- Traditional Anticoagulation Therapies:
There has been a noticeable decrease in studies solely focused on traditional anticoagulation therapies such as warfarin, as newer direct oral anticoagulants gain prominence and become the focus of research. - Case Reports of Rare Disorders:
The frequency of case reports detailing rare coagulation disorders seems to be waning, possibly due to a shift towards more comprehensive studies that aggregate data across multiple cases rather than focusing on singular instances. - Basic Science Studies:
Basic science studies that explore fundamental mechanisms of coagulation without direct clinical applications are appearing less frequently, as the journal pivots towards research with immediate clinical relevance. - Historical Perspectives on Coagulation Disorders:
There is a decline in publications that address historical perspectives or traditional views on coagulation disorders, indicating a shift towards contemporary and evidence-based practices.
Similar Journals
Hamostaseologie
Pioneering Research in Coagulation: Your Gateway to Hematological InsightsHamostaseologie is a prominent academic journal dedicated to the field of hematology, published by GEORG THIEME VERLAG KG. With an ISSN of 0720-9355 and an E-ISSN of 2567-5761, this journal has been at the forefront of critical research and advancements since its inception in 1981, and it continues to maintain its relevance in the scientific community with a converged publication until 2024. Ranked in the Q3 quartile in Hematology for 2023, and positioned at #44 out of 137 in the Scopus Medicine Hematology category, it represents a substantial contribution to scholarly discourse. Researchers and professionals alike will find valuable insights within its pages, as it disseminates rigorous studies and reviews that address pertinent issues related to hemostasis and coagulation. While the journal does not currently offer Open Access, readers can access its valuable content through institutional subscriptions, making it an essential resource for students, clinicians, and researchers aiming to deepen their understanding of hematological science.
Journal of Hematology
Empowering Research, Transforming LivesThe Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.
Journal of Blood Medicine
Empowering Research: Your Gateway to Innovations in HematologyThe Journal of Blood Medicine, published by DOVE MEDICAL PRESS LTD, stands as a vital resource in the field of hematology, focusing on the latest research developments and clinical advancements in blood medicine. With an impact factor reflective of its growing relevance, this open-access journal has been delivering quality scholarly work since 2010, ensuring that critical research is readily available to the global scientific community. The journal operates under an open-access model, further enhancing its dissemination and accessibility to researchers, professionals, and students alike. In the 2023 rankings, it secured a Q3 category status within hematology and achieved a commendable 76th rank out of 137 in Scopus listings, indicating its commitment to quality and innovation in this specialized area. Located in New Zealand, the journal's diverse topics encompass clinical research, treatment modalities, and emerging therapies, contributing significant insights vital for shaping future advancements in blood medicine.
International Journal of Laboratory Hematology
Pioneering insights in hematology for a healthier tomorrow.The International Journal of Laboratory Hematology, published by WILEY, serves as a vital resource in the field of hematology, delivering high-quality research findings and innovations within laboratory practices since its inception in 2007. This journal, accessible under Open Access options, showcases cutting-edge studies that span critical aspects of biochemistry and clinical laboratory methodologies. With a notable impact factor reflected in its Q2 and Q3 rankings across various categories—such as Biochemistry (medical) and Hematology—this journal stands out within the Scopus rankings, positioning itself within the 60th and 59th percentiles of its respective fields. Situated in the United Kingdom, the journal's objectives lie in disseminating pivotal research that enhances our understanding of hematological disorders and laboratory techniques, making it an essential tool for researchers, professionals, and students alike who are committed to advancing the science of laboratory hematology and its applications.
LEUKEMIA & LYMPHOMA
Elevating the standards of hematological research.LEUKEMIA & LYMPHOMA is a prestigious peer-reviewed journal published by Taylor & Francis Ltd, focusing on vital research in the fields of hematology, oncology, and cancer research. With an ISSN of 1042-8194 and an E-ISSN of 1029-2403, this journal is recognized for its high-quality and impactful contributions to understanding blood cancers, with a notable impact factor reflective of its influence. Since its inception in 1989, LEUKEMIA & LYMPHOMA has continuously provided a platform for researchers and professionals to disseminate their findings, fostering advancements in diagnostic, therapeutic, and clinical strategies related to leukemias and lymphomas. The journal ranks in the Q2 category for both Hematology and Oncology research categories as of 2023, underscoring its commitment to excellence. The journal is based in the United Kingdom and serves a global audience, making it an essential resource for those dedicated to improving outcomes for patients with hematological malignancies.
Research and Practice in Thrombosis and Haemostasis
Bridging gaps in knowledge for hematology experts.Research and Practice in Thrombosis and Haemostasis, published by Elsevier, is a prominent open-access journal dedicated to advancing the field of hematology through high-quality research and clinical practice. Since its inception in 2017, this journal has established itself as a vital resource for researchers, healthcare professionals, and students interested in thrombosis and hemorrhage management, showcasing original research, reviews, and clinical studies. The journal’s commitment to accessible knowledge is reflected in its open-access model, allowing researchers worldwide to share their findings without financial barriers. With an impressive 2023 Scopus rank of #42 out of 137 in the hematology category and a respectable Q2 classification, it provides an authoritative platform for innovative ideas and cutting-edge developments in the field. As the journal continues to grow in stature, it aims to foster collaboration and knowledge exchange amongst professionals dedicated to improving patient outcomes in thrombosis and hemostasis.
GEMATOLOGIYA I TRANSFUZIOLOGIYA
Pioneering Research for a Healthier TomorrowGEMATOLOGIYA I TRANSFUZIOLOGIYA is an esteemed journal published by the MINISTERSTVO ZDRAVOOKHRANENIYA in the Russian Federation, focusing on the vital fields of hematology and transfusion medicine. With a rich history dating back to its inception in 1983, the journal plays a significant role in disseminating critical research and advancements in these areas, particularly relevant given the evolving landscape of medical science. As a recognized publication, it is indexed in Scopus and holds a Q4 category ranking in Hematology for 2023, reflecting its niche but important contributions to the field. Researchers, healthcare professionals, and students can look forward to a variety of peer-reviewed articles that not only address contemporary issues but also pave the way for innovative practices in hematology. Although it does not currently offer open access, the journal remains a valuable resource for those seeking to stay informed about the latest findings and developments.
Turkish Journal of Hematology
Connecting researchers and clinicians to elevate hematology practices.Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.
ANNALS OF HEMATOLOGY
Empowering the scientific community with quality contributions.ANNALS OF HEMATOLOGY, published by Springer in Germany, stands as a premier platform for advancing knowledge in the field of hematology and medicine at large. With a significant impact factor and recognized rankings—Q2 in Hematology and Q1 in Medicine (miscellaneous) as of 2023—this journal is pivotal for researchers, clinicians, and students who are keen on exploring the latest developments in blood disorders, treatments, and innovative methodologies. Its broad scope encompasses original research, reviews, and discussions that aim to foster interdisciplinary dialogue, ensuring that the latest findings and theories are accessible to the scientific community. Although not an open-access journal, its rigorous peer-review process guarantees high-quality contributions, thereby solidifying its reputation as a vital resource in the hematological field. Founded in 1991, the ANNALS OF HEMATOLOGY continues to evolve, converging invaluable insights from both basic and clinical research until 2024. For those dedicated to improving patient outcomes and advancing hematological science, this journal remains an essential reference.
THROMBOSIS AND HAEMOSTASIS
Advancing the Frontiers of Hematology ResearchTHROMBOSIS AND HAEMOSTASIS is a prestigious journal published by GEORG THIEME VERLAG KG, dedicated to advanced research in the field of hematology. With an esteemed Impact Factor and recognized as Q1 in its category for 2023, the journal is regarded for its pivotal role in disseminating significant findings that contribute to our understanding of thrombosis and hemostasis. Since its inception in 1976, this journal has continuously published cutting-edge studies and reviews, making it a vital resource for researchers, healthcare professionals, and students alike. The journal’s commitment to high-quality research is reflected in its impressive Scopus Ranking of #18 out of 137 in Medicine - Hematology, placing it in the 87th percentile among its peers. Although not currently open access, THROMBOSIS AND HAEMOSTASIS remains an authoritative source for exploring novel therapeutic strategies and the latest scientific advancements in the field. Based in Stuttgart, Germany, this journal serves as a critical platform for sharing knowledge and fostering collaboration within the global hematology community.